A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)
Julie A. Means‐Powell, Ingrid A. Mayer, Roohi Ismail‐Khan, Luis Del Valle, Debra A. Tonetti, Vandana G. Abramson, Melinda Sanders, Richard M. Lush, Claudia Sorrentino, Samarpan Majumder, Lucio Miele
Topics & Concepts
MedicineExemestaneMetastatic breast cancerBreast cancerRashInternal medicineFulvestrantOncologyTolerabilityCancerEstrogen receptorTamoxifenProgressive diseaseAdverse effectDiseaseEstrogen and related hormone effectsPI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer Research